Ignite Creation Date:
2025-12-24 @ 6:37 PM
Ignite Modification Date:
2026-01-05 @ 1:00 PM
Study NCT ID:
NCT06217757
Status:
RECRUITING
Last Update Posted:
2024-05-13
First Post:
2024-01-11
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
Sponsor:
Sichuan University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-04-18
Start Date Type:
ACTUAL
Primary Completion Date:
2026-06-20
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-03-20
Completion Date Type:
ESTIMATED
First Submit Date:
2024-01-11
First Submit QC Date:
None
Study First Post Date:
2024-01-22
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-05-09
Last Update Post Date:
2024-05-13
Last Update Post Date Type:
ACTUAL